MS39 (compound 6) 是一种靶向 EGFR 的 PROTAC,可降低 HCC-827 和 H3255 细胞中 EGFR 及下游信号的表达,并抑制 H3255 细胞的增殖(粉色:EGFR 配体 (MS-C70290);蓝色:VHL 配体 (MS-L68940);黑色:连接子 (MS-F64935))。
产品编号: MS-G83896 纯度: 99.89% CAS No.: 2675490-92-1 分子式: C55H71ClFN9O7S 分子量: 1056.72
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

MS39 (compound 6) 是一种靶向 EGFR 的 PROTAC,可降低 HCC-827 和 H3255 细胞中 EGFR 及下游信号的表达,并抑制 H3255 细胞的增殖(粉色:EGFR 配体 (MS-C70290);蓝色:VHL 配体 (MS-L68940);黑色:连接子 (MS-F64935))。

生物实验数据

生物活性 MS39 (compound 6) is an EGFR-targeting PROTAC that decreases EGFR and downstream signaling expression in HCC-827 and H3255 cells and inhibits the proliferation of H3255 cells (pink: EGFR ligand (MS-C70290); blue: VHL ligand (MS-L68940); black: linker (MS-F64935)).
体外研究
(In Vitro)

MS39 在竞争性结合实验中可高亲和力结合纯化的野生型 EGFR (Kd=11 nM) 和 EGFRL858R 突变体蛋白 (Kd=12 nM)。
MS39 (1-10000 nM; 16 h) 可在 HCC-827 细胞中强效诱导 EGFR e19d 的浓度依赖性降解,16 h 内的 DC50 为 5.0 nM,并可抑制下游 EGFR-AKT 信号通路。
MS39 (1-10000 nM; 16 h) 可在 H3255 细胞中强效诱导 EGFRL858R 产生浓度依赖性降解,16 h 内的 DC50 为 3.3 nM,同时可抑制下游 EGFR-AKT 信号通路。

Western Blot Analysis

Cell Line: HCC-827 lung cancer cells (expressing EGFR with exon 19 deletion, EGFR e19d)
Concentration: 1-10000 nM
Incubation Time: 16 h
Result: Induced concentration-dependent degradation of EGFR e19d, achieving over 95% maximum degradation at 50 nM.
Reached a half-maximal degradation concentration (DC50) of 5.0 nM.
Showed a slight "hook effect" at 10000 nM.
Potently inhibited EGFR autophosphorylation (p-EGFR) and AKT phosphorylation (p-AKT).

Western Blot Analysis

Cell Line: H3255 lung cancer cells (expressing EGFR L858R mutant)
Concentration: 1-10000 nM
Incubation Time: 16 h
Result: Induced concentration-dependent degradation of EGFR L858R, achieving over 95% maximum degradation at 50 nM.
Reached a half-maximal degradation concentration (DC50) of 3.3 nM.
Showed no "hook effect" at 10000 nM.
Potently inhibited EGFR autophosphorylation (p-EGFR) and AKT phosphorylation (p-AKT).

Western Blot Analysis

Cell Line: OVCAR-8 ovarian cancer cells (expressing wild-type EGFR), H1299 lung cancer cells (expressing wild-type EGFR)
Concentration: 1-10000 nM
Incubation Time: 16 h
Result: Did not significantly reduce WT EGFR protein levels in either cell line.

Western Blot Analysis

Cell Line: HCC-827 lung cancer cells (expressing EGFR e19d)
Concentration: 100 nM
Incubation Time: 0, 1, 2, 4, 8, 12, 24 h
Result: Induced time-dependent degradation of EGFR e19d, reducing EGFR protein levels by ~50% after 4 h.
Achieved near-complete degradation by 12 h, and sustained complete degradation for up to 24 h.
Reached a half-life (t1/2) of EGFR degradation of 4 h.
Showed robust inhibition of p-AKT after 1 h of treatment.

Western Blot Analysis

Cell Line: H3255 lung cancer cells (expressing EGFR L858R mutant)
Concentration: 100 nM
Incubation Time: 0, 1, 2, 4, 8, 12, 24 h
Result: Induced time-dependent degradation of EGFR L858R, reducing EGFR protein levels by ~50% after 4 h.
Achieved near-complete degradation by 12 h, and sustained complete degradation for up to 24 h.
Reached a half-life (t1/2) of EGFR degradation of 4 h.
Showed inhibition of p-AKT in a time-dependent manner.

Western Blot Analysis

Cell Line: HCC-827 lung cancer cells (expressing EGFR e19d)
Concentration: 100 nM, 1000 nM
Incubation Time: 16 h
Result: Showed a more pronounced EGFR degradation effect in serum-free medium compared to medium containing 10% FBS.

Western Blot Analysis

Cell Line: H3255 lung cancer cells (expressing EGFR L858R mutant)
Concentration: 100 nM, 1000 nM
Incubation Time: 16 h
Result: Showed a more pronounced EGFR degradation effect in serum-free medium compared to medium containing 20% FBS.

Western Blot Analysis

Cell Line: H3255 lung cancer cells (expressing EGFR L858R mutant)
Concentration: 100 nM (MS39; 8 h), 2 h pretreatments with blocking agents
Incubation Time: 8 h (MS39 treatment), 2 h (pretreatment with blocking agents)
Result: Induced EGFR degradation that was blocked by pretreatment with MLN4924, VH-298, or gefitinib.

Western Blot Analysis

Cell Line: HCC-827 lung cancer cells (expressing EGFR e19d)
Concentration: 100 nM
Incubation Time: 12 h (treatment), 0, 1, 2, 4, 8, 12, 24, 48 h (post-washout analysis)
Result: Induced EGFR degradation with EGFR protein levels recovering by 24 h post-washout.
Induced inhibition of p-EGFR with recovery by 24 h post-washout.
Induced inhibition of p-AKT with recovery by 48 h post-washout.

Western Blot Analysis

Cell Line: H3255 lung cancer cells (expressing EGFR L858R mutant)
Concentration: 100 nM
Incubation Time: 12 h (treatment), 0, 1, 2, 4, 8, 12, 24, 48 h (post-washout analysis)
Result: Induced EGFR degradation with EGFR protein levels recovering by 24 h post-washout.
Showed slightly prolonged EGFR degradation and autophosphorylation inhibition compared to HCC-827 cells.

Cell Proliferation Assay

Cell Line: H3255 lung cancer cells (expressing EGFR L858R mutant)
Concentration: Serial dilution series
Incubation Time: 3 days
Result: Effectively inhibited H3255 cell proliferation.
Was more potent than its negative control compound 27 (MS39N) and the previously reported EGFR degrader PROTAC3.
体内研究
(In Vivo)

MS39 (50 mg/kg; i.p.; single dose) 可在雄性瑞士白化小鼠体内达到并维持较高的血浆浓度,24 小时内其浓度仍保持在 1 μM 以上。

Animal Model: Swiss Albino (male)
Dosage: 50 mg/kg
Administration: i.p.; single dose
Result: Maintained high plasma concentrations (approximately 5 μM) for over 8 hours post-dosing.
Measured approximately 1 μM plasma concentration at 24 hours post-dosing.
性状 固体
颜色 White to off-white

化学信息

分子量 1056.72
分子式 C55H71ClFN9O7S
CAS No. 2675490-92-1

储存&溶解度

储存方式

-20°C, protect from light, stored under nitrogen

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (94.63 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM0.9463 mL4.7316 mL9.4632 mL23.6581 mL
5 mM0.1893 mL0.9463 mL1.8926 mL4.7316 mL
10 mM0.0946 mL0.4732 mL0.9463 mL2.3658 mL
15 mM0.0631 mL0.3154 mL0.6309 mL1.5772 mL
20 mM0.0473 mL0.2366 mL0.4732 mL1.1829 mL
25 mM0.0379 mL0.1893 mL0.3785 mL0.9463 mL
30 mM0.0315 mL0.1577 mL0.3154 mL0.7886 mL
40 mM0.0237 mL0.1183 mL0.2366 mL0.5915 mL
50 mM0.0189 mL0.0946 mL0.1893 mL0.4732 mL
60 mM0.0158 mL0.0789 mL0.1577 mL0.3943 mL
80 mM0.0118 mL0.0591 mL0.1183 mL0.2957 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础